U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

MedGen UID:
1618756
•Concept ID:
C4527337
•
Neoplastic Process

Definition

Primary cutaneous diffuse large B-cell lymphoma, leg type that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Professional guidelines

PubMed

Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type.
Oka S, Ono K, Nohgawa M
Ann Hematol 2022 Oct;101(10):2353-2354. Epub 2022 Aug 9 doi: 10.1007/s00277-022-04899-4. PMID: 35943589

Recent clinical studies

Etiology

Primary cutaneous marginal zone lymphoma presenting with secondary chilblains of the toes.
Nasir AZ, Burmeister RS
BMJ Case Rep 2023 Aug 27;16(8) doi: 10.1136/bcr-2023-255894. PMID: 37640411Free PMC Article
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.
Ducharme O, Beylot-Barry M, Pham-Ledard A, Bohers E, Viailly PJ, Bandres T, Faur N, Frison E, Vergier B, Jardin F, Merlio JP, Gros A
J Invest Dermatol 2019 Nov;139(11):2334-2342.e8. Epub 2019 May 29 doi: 10.1016/j.jid.2019.05.008. PMID: 31150604
Can cutaneous low-grade B-cell lymphoma transform into primary cutaneous diffuse large B-cell lymphoma? An immunohistochemical study of 82 cases.
Plaza JA, Kacerovska D, Sangueza M, Schieke S, Buonaccorsi N, Suster S, Kazakov DV
Am J Dermatopathol 2014 Jun;36(6):478-82. doi: 10.1097/DAD.0000000000000009. PMID: 24698933
Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
Fabbri A, Cencini E, Alterini R, Rubegni P, Rigacci L, Delfino C, Puccini B, Fimiani M, Bosi A, Bocchia M, Pimpinelli N; Gruppo Italiano Linfomi Cutanei (GILC)
Eur J Haematol 2014 Aug;93(2):129-36. Epub 2014 Apr 4 doi: 10.1111/ejh.12315. PMID: 24635751

Diagnosis

Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-Cell Lymphoma, Leg-Type: A Case Report.
Zoli S, Pellegrini C, Casadei B, Broccoli A, Argnani L, Nanni L, Stefoni V, Zinzani PL
Chemotherapy 2024;69(1):23-26. Epub 2023 Nov 1 doi: 10.1159/000534784. PMID: 37913761
Primary cutaneous marginal zone lymphoma presenting with secondary chilblains of the toes.
Nasir AZ, Burmeister RS
BMJ Case Rep 2023 Aug 27;16(8) doi: 10.1136/bcr-2023-255894. PMID: 37640411Free PMC Article
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.
Ducharme O, Beylot-Barry M, Pham-Ledard A, Bohers E, Viailly PJ, Bandres T, Faur N, Frison E, Vergier B, Jardin F, Merlio JP, Gros A
J Invest Dermatol 2019 Nov;139(11):2334-2342.e8. Epub 2019 May 29 doi: 10.1016/j.jid.2019.05.008. PMID: 31150604

Therapy

Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
Treatment of refractory diffuse large B-cell lymphoma by chidamide combined with autologous stem cell transplantation: a case report.
Wu P, Ma T, Chen Y, Wang F, Chen Y, Gao J, Zhou Z, Jia Y
Anticancer Drugs 2021 Sep 1;32(8):886-889. doi: 10.1097/CAD.0000000000001093. PMID: 34145178
Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.
Ducharme O, Beylot-Barry M, Pham-Ledard A, Bohers E, Viailly PJ, Bandres T, Faur N, Frison E, Vergier B, Jardin F, Merlio JP, Gros A
J Invest Dermatol 2019 Nov;139(11):2334-2342.e8. Epub 2019 May 29 doi: 10.1016/j.jid.2019.05.008. PMID: 31150604
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.
Beylot-Barry M, Mermin D, Maillard A, Bouabdallah R, Bonnet N, Duval-Modeste AB, Mortier L, Ingen-Housz-Oro S, Ram-Wolff C, Barete S, Dalle S, Maubec E, Quereux G, Templier I, Bagot M, Grange F, Joly P, Vergier B, Vially PJ, Gros A, Pham-Ledard A, Frison E, Merlio JP
J Invest Dermatol 2018 Sep;138(9):1982-1989. Epub 2018 Mar 27 doi: 10.1016/j.jid.2018.03.1516. PMID: 29596904
Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
Fabbri A, Cencini E, Alterini R, Rubegni P, Rigacci L, Delfino C, Puccini B, Fimiani M, Bosi A, Bocchia M, Pimpinelli N; Gruppo Italiano Linfomi Cutanei (GILC)
Eur J Haematol 2014 Aug;93(2):129-36. Epub 2014 Apr 4 doi: 10.1111/ejh.12315. PMID: 24635751

Prognosis

Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.
Ducharme O, Beylot-Barry M, Pham-Ledard A, Bohers E, Viailly PJ, Bandres T, Faur N, Frison E, Vergier B, Jardin F, Merlio JP, Gros A
J Invest Dermatol 2019 Nov;139(11):2334-2342.e8. Epub 2019 May 29 doi: 10.1016/j.jid.2019.05.008. PMID: 31150604
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.
Beylot-Barry M, Mermin D, Maillard A, Bouabdallah R, Bonnet N, Duval-Modeste AB, Mortier L, Ingen-Housz-Oro S, Ram-Wolff C, Barete S, Dalle S, Maubec E, Quereux G, Templier I, Bagot M, Grange F, Joly P, Vergier B, Vially PJ, Gros A, Pham-Ledard A, Frison E, Merlio JP
J Invest Dermatol 2018 Sep;138(9):1982-1989. Epub 2018 Mar 27 doi: 10.1016/j.jid.2018.03.1516. PMID: 29596904
Can cutaneous low-grade B-cell lymphoma transform into primary cutaneous diffuse large B-cell lymphoma? An immunohistochemical study of 82 cases.
Plaza JA, Kacerovska D, Sangueza M, Schieke S, Buonaccorsi N, Suster S, Kazakov DV
Am J Dermatopathol 2014 Jun;36(6):478-82. doi: 10.1097/DAD.0000000000000009. PMID: 24698933
Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
Fabbri A, Cencini E, Alterini R, Rubegni P, Rigacci L, Delfino C, Puccini B, Fimiani M, Bosi A, Bocchia M, Pimpinelli N; Gruppo Italiano Linfomi Cutanei (GILC)
Eur J Haematol 2014 Aug;93(2):129-36. Epub 2014 Apr 4 doi: 10.1111/ejh.12315. PMID: 24635751

Clinical prediction guides

Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.
Ducharme O, Beylot-Barry M, Pham-Ledard A, Bohers E, Viailly PJ, Bandres T, Faur N, Frison E, Vergier B, Jardin F, Merlio JP, Gros A
J Invest Dermatol 2019 Nov;139(11):2334-2342.e8. Epub 2019 May 29 doi: 10.1016/j.jid.2019.05.008. PMID: 31150604

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...